Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Patients treated with tirzepatide have shown reductions in ALT and AST levels when these were elevated at baseline
In one study, around 13% of people reported nausea within the first three months of taking Ozempic
Semaglutides cardiovascular benefit data (the SELECT trial, 2023) remains a distinct advantage for high-risk patients, and this consideration may guide some providers to recommend semaglutide even for patients currently on tirzepatide
Population: Adults aged 18 years with type 2 diabetes mellitus (T2DM) and/or obesity (BMI 30 kg/m2)
US$ 22.76
US$ 29.24
US$ 27.51
US$ 26.07
